| Detected | Trial | Change |
|---|---|---|
| 2026-05-27 | NCT06188702 S095035 as a Single Agent and in Combination in Adult Participants With Advanced or… |
overall status: "Recruiting" → "Active Not Recruiting" |
| 2026-05-27 | NCT06188702 S095035 as a Single Agent and in Combination in Adult Participants With Advanced or… |
Enrollment reduced: 342 -> 60 participants |
| 2026-05-27 | NCT06188702 S095035 as a Single Agent and in Combination in Adult Participants With Advanced or… |
Trial sites reduced: 35 -> 22 locations |
| 2026-05-27 | NCT06188702 S095035 as a Single Agent and in Combination in Adult Participants With Advanced or… |
date change Primary completion moved earlier: 2031-10-31 -> 2027-05-01 |
| 2026-05-27 | NCT06188702 S095035 as a Single Agent and in Combination in Adult Participants With Advanced or… |
date change Completion moved earlier: 2031-10-31 -> 2027-05-01 |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 1/2 | |||
| NCT05732831 | Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors | Locally Advanced Solid Tumor | Recruiting |
| NCT06922591 | Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC &… | PDAC | Recruiting |
| NCT06188702 | S095035 as a Single Agent and in Combination in Adult Participants With Advanced or… | MTAP-deleted Solid Tumors | Active, Not Recruiting |